ACXP

Acurx Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.080

-0.02(-0.488%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

4.220

Open

4.080

VWAP

4.02

Vol

69.85K

Mkt Cap

6.47M

Low

3.900

Amount

280.69K

EV/EBITDA(TTM)

Total Shares

15.84M

242.60K

EV/OCF(TTM)

P/S(TTM)

Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug-resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

-1.410

-35.91%

-1.425

-55.47%

-1.285

-62.21%

Estimates Revision

The market is revising No Change the revenue expectations for Acurx Pharmaceuticals, Inc. (ACXP) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -66.14%.

EPS Estimates for FY2025

Revise Downward

-12.68%

In Past 3 Month

Stock Price

Go Down

-66.14%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is 30.50 USD with a low forecast of 30.00 USD and a high forecast of 31.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.080

Low

30.00

Averages

30.50

High

31.00

Current: 4.080

Low

30.00

Averages

30.50

High

31.00

H.C. Wainwright

NULL -> Buy

upgrade

$8 -> $31

2025-08-12

Reason

H.C. Wainwright

Price Target

$8 -> $31

2025-08-12

upgrade

NULL -> Buy

Reason

H.C. Wainwright adjusted the firm's price target on Acurx to $31 from $8 and keeps a Buy rating on the shares following the recent 1-for-20 reverse stock split. The firm believes the company's lead asset ibezapolstat is making steady progress as it prepares to enter Phase 3 evaluation.

H.C. Wainwright

NULL

Buy

initiated

2025-05-15

Reason

H.C. Wainwright

Price Target

2025-05-15

initiated

NULL

Buy

Reason

H.C. Wainwright assumed coverage of Acurx with a Buy rating and $8 price target. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria, the analyst tells investors in a research note. The firm believes the company is "flying under the radar with investors" into a "paradigm shifting moment in anti-infectives."

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$12

2025-03-19

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$12

2025-03-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$12

2025-01-13

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$12

2025-01-13

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$12

2025-01-10

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$12

2025-01-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Ed Arce

Strong Buy

Reiterates

$12

2024-12-10

Reason

HC Wainwright & Co.

Ed Arce

Price Target

$12

2024-12-10

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Acurx Pharmaceuticals Inc (ACXP.O) is -0.73, compared to its 5-year average forward P/E of -2.44. For a more detailed relative valuation and DCF analysis to assess Acurx Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.44

Current PE

-0.73

Overvalued PE

-1.23

Undervalued PE

-3.66

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.04

Current EV/EBITDA

-0.04

Overvalued EV/EBITDA

0.10

Undervalued EV/EBITDA

-0.18

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.03

Current PS

0.00

Overvalued PS

0.28

Undervalued PS

-0.21